






Common C	c Over Prescribing: Clinical Situations a mative Therapy	nd
Clinical Situation	Alternative Therapy to Antibiotics	
Asymptomatic Bacteremia	Monitor vital signs, and for any symptoms	
Cloudy/ Malodorous Urine	Scheduled toileting, perineal cleansing, increase fluid intake	
Non-specific Symptoms $ ightarrow$ Test for UTI	Consider other factors/possible get UA	
Upper Respiratory Infections	Supportive Therapy	
Bronchitis without COPD	Symptomatic Treatment, Bronchodilators for those with wheezing/bothersome cough	
Influenza without secondary infection	Antiviral therapy	
Khandelwal C, et al. Ann Longterm Care 2012;20[4]:23-29		4










































_	SUBJECT: Antimicrobial Stewardship Program	
To act	rpose: form and maintain a committee that establishes and enforces commitments and ions designed to improve antimicrobial use with the goal of enhancing patient health comes, reducing resistance to antibiotics, and decreasing unnecessary cost.	
Th	licy: e facility will maintain an interdisciplinary antimicrobial stewardship program (ASP) that fines and provides guidance for optimal antimicrobial use.	
Pre	pcedure:	
1. 2.	The ASP and members will have accountability to the facilities Quality Assurance/Performance improvement committee. The ASP will give updates quarterly to the QAPI committee. The membership of the ASP will be comprised of at a minimum: the medical director, the director of pharmacy, and the infection control specialist. a. The medical director will set the standard for antimicrobial prescribing b. Infection control specialist will establish the standards for nursing: Assessment	
	 Monitoring and communication of changes in condition when an infection is suspected The director of pharmacy will set standards for dispensing/consultant pharmacist to review antimicrobial orders upon dispensation/during monthly medication regimen review to ensure antimicrobials are appropriately ordered and monitored. "For more detailed responsibilities please refer to appendix 1 of this policy 	
3.	The members of the ASP will develop, educate and enforce protocols for use by the facility staff for appropriate identification and assessment of infections and treatment quidelines.	
4.	treatment guidelines. The members of the ASP committee will meet at least monthly to review collected data and facility trends, analyze performance, and develop action plans to improve antimicrobial use.	



















PARKER	Commo	nt Pathway for Infections	
Г	First Line Therapy	Cephalexin PO	
	Second Line Therapy	Nitrofurantoin PO	
	Third Line Therapy	Bactrim DS PO	
-	Fourth Line Therapy	Fosfomycin PO	
	Empiric Antibiotic Therapy	for UTI <u>With</u> Pyelonephritis	
[First Line Therapy	Ceftriaxone IVPB/IM	
ļ	Second Line Therapy	Cefpodoxime PO	
	PCN Allergy	Aztreonam IVPB/IM	
-	Empiric Antibiotic Therapy fo	r Complicated ESBL UTI history	
Γ	First Line Therapy	Meropenem IVPB	
Let a let	Second Line Therapy	Ertapenem* IM	
L		*will not cover pseudomonas	
		2	28






Medication/ Drug Classes	Laboratory lest
Amikacin, Gentamicin, Tobramycin	Peaks and Troughs (baseline at steady state and weekly for duration of therapy) SMA-7 (weekly for duration of therapy)
Vancomycin	Random level (baseline at steady state and weekly for duration of therapy) SMA-7 (weekly for duration of therapy)
Daptomycin	CPK (weekly for duration of therapy)
Linezolid	CBC (weekly for duration of therapy)
Warfarin	INR (Baseline, placed on interacting medication per policy, over 30 days since last INR)
Polymyxin B	SMA-7 (weekly for duration of therapy)

31



- **<u>Primary objective</u>**: Determine incidence of acute kidney injury in patients who received vancomycin a year before and a year after implementation therapeutic monitoring policy
- <u>Secondary objectives</u>: Assess percentage of vancomycin troughs in therapeutic range and compliance with laboratory testing
- Inclusion Criteria:
 - 18 years or older
 - Received <u>></u>4 doses of IV vancomycin
 - Drug levels were ordered
 - CrCl <u>></u>15 mL/min utilizing Cockcroft-Gault
 - Not on hemodialysis


mith AP et al. Consult Pharm. 2016 Sep:31(9):505-10.







Impact of a Pharmacy Practice Collaborative Practice on Monitoring Vancomycin in a Long Term Care Facility


Scenario	Compliance if:
Vancomycin initiated outside the nursing facility	Level obtained weekly
Vancomycin initiated in the nursing facility	Level obtained between fourth and sixth doses, then weekly
Vancomycin dose adjusted in the nursing facility	Level obtained between fourth and sixth doses, then weekly

























































Summary

- The majority of residents in LTCF will have at least 1 course of system antibiotic use during the course of the year
- A large proportion of this antibiotic utilization is unnecessary and inappropriate
- Pharmacist working in the LTCF setting can help to ensure optimal antibiotic pharmacotherapy and compliance with regulations by assisting in development of antibiotic stewardship practices at the institutions they practice

55

